1. CBO nearly doubles estimated savings from generic biologics. FDA Week. December 26, 2008.
2. Insmed, Inc. Study by leading economist identifies potential for $378 billion of savings from follow on biologics [press release]. February 11, 2008. https://doi.org/investor.insmed.com/releasedetail.cfm?ReleaseID=293143.
3. European Generics Association. FAQ on biosimilar medicines, https://doi.org/www.egagenerics.com/FAQ-biosimilars.htm. Last accessed April 7, 2009.
4. European Parliament and Council Directive 2004/27/EC of 31 March 2004. OJ. April 30, 2004. L 136/34, https://doi.org/eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0034:0057:EN:PDF. Accessed April 9, 2009.
5. Covington and Burling LLP. 2006. FDA approval of Sandoz's 505(b)